Real-world outcomes with different technology modalities in type 1 diabetes

Beato-Víbora, Pilar Isabel; Gallego-Gamero, Fabiola; Ambrojo-López, Ana

doi:10.1016/j.numecd.2021.02.028

Cited by 13 publications

(7 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, we reported that in children and adolescents, the perceived benefits of CGM use were associated with TIR and reduced glucose variability, regardless of the technology used, and here we speculate that in the same subjects, CGM satisfaction is the key factor related to QoL. Other studies have analysed real-world clinical but not psychological outcomes related to different technology modalities in T1D, [25][26][27][28] and a recent survey of youths between 2 and 16 years of age analysed HRQoL, but only 16.8% of them used a CGM. 29 The KINDL questionnaire adopted here to measure generic aspects of QoL (physical health, emotional and school functioning), combined with the assessment of diabetes-specific dimensions, provided a more comprehensive analysis of satisfaction, health, well-being and burden commonly associated with the management of diabetes, expanding knowledge about the relationship between CGM satisfaction and QoL.…”

Section: Discussionmentioning

confidence: 53%

Satisfaction with continuous glucose monitoring is associated with quality of life in young people with type 1 diabetes regardless of metabolic control and treatment type

Franceschi,

Pertile,

Marigliano

et al. 2024

Diabet Med

View full text Add to dashboard Cite

AimsWhile continuous glucose monitoring (CGM) and associated technologies have positive effects on metabolic control in young people with type 1 diabetes (T1D), less is known about their impact on quality of life (QoL). Here, we quantified CGM satisfaction and QoL in young people with T1D and their parents/caregivers to establish (i) the relationship between QoL and CGM satisfaction and (ii) the impact of the treatment regimen on QoL.MethodsThis was a cross‐sectional study of children and adolescents with T1D on different treatment regimens (multiple daily injections, sensor‐augmented pumps and automated insulin delivery). QoL was assessed with the KINDL instrument, and CGM satisfaction with the CGM‐SAT questionnaire was evaluated in both youths with T1D and their parents.ResultsTwo hundred and ten consecutively enrolled youths with T1D completed the KINDL and CGM‐SAT questionnaires. The mean total KINDL score was greater than neutral in both subjects with T1D (3.99 ± 0.47) and parents (4.06 ± 0.40), and lower overall CGM‐SAT scores (i.e., higher satisfaction) were significantly associated with higher QoL in all six KINDL subscales (p < 0.05). There were no differences in KINDL scores according to delivery technology or when participants were grouped according to optimal and sub‐optimal glucose control.ConclusionsHigher satisfaction with recent CGMs was associated with better QoL in all dimensions. QoL was independent of both the insulin delivery technology and glycaemic control. CGM must be further disseminated. Attention on perceived satisfaction with CGM should be incorporated with the clinical practice to improve the well‐being of children and adolescents with T1D and their families.

show abstract

Section: Discussionmentioning

confidence: 53%

Satisfaction with continuous glucose monitoring is associated with quality of life in young people with type 1 diabetes regardless of metabolic control and treatment type

Franceschi,

Pertile,

Marigliano

et al. 2024

Diabet Med

View full text Add to dashboard Cite

show abstract

“…Closed‐loop systems offer the maximum benefit in terms of TIR, versus isCGM with or without CSII, and can achieve TIRs of over 80% in studies in adults, with most of the remaining time in hyperglycemia (TAR1 and TAR2), especially postprandially 19–22 …”

Section: Discussionmentioning

confidence: 99%

“…Closed-loop systems offer the maximum benefit in terms of TIR, versus isCGM with or without CSII, and can achieve TIRs of over 80% in studies in adults, with most of the remaining time in hyperglycemia (TAR1 and TAR2), especially postprandially. [19][20][21][22] In our study, we evaluated metabolic control in children with isCGM+CSII who switched to the Medtronic 780G system, according to the variables defined following the introduction of sensor-based glucose monitoring, as in other studies with these characteristics. Our cutoffs for good control are the typical cutoffs used in other studies, differentiating in our case, as in Víbora et al, between the cutoffs 70-180 mg/dL (TIR), <70 mg/dL (TBR1), <54 mg/dL (TBR2), 180-250 mg/dL (TAR1), and >250 mg/dL (TAR2).…”

Section: Discussionmentioning

confidence: 99%

Impact on glucometric variables and quality of life of the advanced hybrid closed‐loop system in pediatric and adolescent type 1 diabetes

Lendínez‐Jurado,

Gómez‐Perea,

Ariza‐Jiménez

et al. 2023

Journal of Diabetes

View full text Add to dashboard Cite

Background: In recent years, technological advances in the field of diabetes have revolutionized the management, prognosis, and quality of life of diabetes patients and their environment. The aim of our study was to evaluate the impact of implementing the MiniMed 780G closed-loop system in a pediatric and adolescent population previously treated with a continuous subcutaneous insulin infusion pump and intermittent glucose monitoring. Methods: Data were collected from 28 patients with type 1 diabetes aged 6 to 17 years, with a follow-up of 6 months. We included both glucometric and quality of life variables, as well as quality of life in primary caregivers. Metabolic control variables were assessed at baseline (before system change) and at different cutoff points after initiation of the closedloop system (48 hours, 7 days, 14 days, 21 days, 1 month, 3 months, 6 months). Results: Time in range 70-180 mg/dL increased from 59.44% at baseline to 74.29% in the first 48 hours after automation of the new system, and this improvement was maintained at the other cutoff points, as was time in hyperglycemia 180-250 mg/dL (24.44% at baseline to 18.96% at 48 hours) and >250 mg/dL (11.71% at baseline to 3.82% at 48 hours). Conclusions: Our study showed an improvement in time in range and in all time spent in hyperglycemia from the first 48 hours after the automation of the system, which was maintained at 6 months. K E Y W O R D S pediatric type 1 diabetes, advanced hybrid closed-loop, time in range, time in hyperglycemia, MiniMed 780G

show abstract

“…In addition, a comparative study highlighted that different technology modalities in T1D, including HCL systems, are associated with improved glycemic control [68]. This study suggests that HCL systems offer significant advantages in terms of time in range and hypoglycemia protection compared to other diabetes management technologies [68].…”

Section: Benefits Of Using Hclss and Insulin Pumps On Diabetic Retino...mentioning

confidence: 99%

Exploring the Impact of Glycemic Control on Diabetic Retinopathy: Emerging Models and Prognostic Implications

Tecce,

Cennamo,

Rinaldi

et al. 2024

JCM

View full text Add to dashboard Cite

This review addresses the complexities of type 1 diabetes (T1D) and its associated complications, with a particular focus on diabetic retinopathy (DR). This review outlines the progression from non-proliferative to proliferative diabetic retinopathy and diabetic macular edema, highlighting the role of dysglycemia in the pathogenesis of these conditions. A significant portion of this review is devoted to technological advances in diabetes management, particularly the use of hybrid closed-loop systems (HCLSs) and to the potential of open-source HCLSs, which could be easily adapted to different patients’ needs using big data analytics and machine learning. Personalized HCLS algorithms that integrate factors such as patient lifestyle, dietary habits, and hormonal variations are highlighted as critical to reducing the incidence of diabetes-related complications and improving patient outcomes.

show abstract

Real-world outcomes with different technology modalities in type 1 diabetes

Cited by 13 publications

References 21 publications

Satisfaction with continuous glucose monitoring is associated with quality of life in young people with type 1 diabetes regardless of metabolic control and treatment type

Satisfaction with continuous glucose monitoring is associated with quality of life in young people with type 1 diabetes regardless of metabolic control and treatment type

Impact on glucometric variables and quality of life of the advanced hybrid closed‐loop system in pediatric and adolescent type 1 diabetes

Exploring the Impact of Glycemic Control on Diabetic Retinopathy: Emerging Models and Prognostic Implications

Contact Info

Product

Resources

About